- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00277017
Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma
A Phase I/II Trial of Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, and Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma.
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
Eligible patients who agree to take part in the study will receive oral dosages of Thalidomide at 200mg/day to start, with dosage gradually increasing up to a maximum of 1200mg/day. This will be taken in combination with:
5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.
Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks.
Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.
Treatment will be followed by 2 weeks of rest then repeated.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87131
- University of New Mexico
-
Albuquerque, New Mexico, États-Unis, 87108
- Lovelace Sandia Health Systems Dept of Hematology
-
Santa Fe, New Mexico, États-Unis
- New Mexico Cancer Care Associates
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- All patients must have histologically proven renal cell carcinoma which is metastatic, non-resectable and/or recurrent.
- Patients must have bidimensionally measurable disease as defined in Section 10.1a documented within 28 days prior to registration. X-rays, scans, or physical exam of all non-measurable disease must be completed within 42 days prior to registration.
- Prestudy chest x-ray must be done within 42 days prior to registration.
- Prior treatment with drugs included in this protocol is permitted if such prior treatment occurred more than 6 months previous or if patient is currently exhibiting minor, mixed or partial response to any of these drugs. Prior treatment with other drugs is allowed as long as therapy was discontinued at least one month previously.
- Prior radiation therapy (to less than 25% of the bone marrow only, see section 19.2), or surgery are allowed. At least 4 weeks must have elapsed since the completion of radiation therapy, and there must be measurable disease outside the radiation fields. At least 3 weeks must have elapsed since completion of surgery.
- Patients must have had an EKG performed within 28 days prior to registration.
- Patients must have a Southwest Oncology Group performance status of 0-2 as defined in Section 10.4.
Exclusion Criteria:
- Patients must not be receiving or planning to receive concomitant biologic therapy, radiation therapy, hormonal therapy, or other chemotherapy while on this protocol (including G/GM-CSF).
- Patients with currently untreated brain metastases or brain metastases on current therapy are not eligible. Patients with prior brain metastases S/P radiation and/or surgery, and with stable response, confirmed by MRI, off corticosteroids may be eligible. Brain MRI within 28 days of treatment and consultation with the Study Coordinator is required for such patients.
- Pregnant or nursing women may not participate. Women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
- Patients with other serious illnesses, serious active infections requiring treatment with antibiotics, those requiring ongoing therapy with other investigational drugs or those receiving or expected to require corticosteroids are not permitted.
- Patients with known AIDS or HIV-1 associated complex or known to be HIV antibody seropositive are not eligible.
- In calculating days of tests and measurements, the day a test or measurement is done is considered Day 0. Therefore, if a test is done on a Monday, the Monday four weeks later would be considered Day 28. This allows for efficient patient scheduling without exceeding the guidelines. If Day 28 or 42 falls on a weekend or holiday, the limit may be extended to the next working day.
- Patients must be informed of the investigational nature of this study and give written in-formed consent in accordance with institutional and federal guidelines.
- Patients must be registered with the UNM Cancer Center Protocol Office. All records and flow sheets must be sent to this office.
- Active substance abuse can lead to unexpected and dangerous drug interactions and toxicities and impair compliance; therefore, this condition is an exclusion to registration or continuation on this study. Patients with a history of substance abuse must have blood or urine testing prior to registration on protocol. Psychosocial screening by the clinic psychologist or social worker is also suggested but not required. Patients found to be actively engaged in substance abuse while on protocol may be discontinued from protocol treatment at the direction of their physician and/or the study coordinator.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Evaluate a therapy combining the established FUNIL regimen with Thalidomide.
Délai: Treatment stopped if there is disease progression or toxicity
|
Treatment stopped if there is disease progression or toxicity
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par type histologique
- Tumeurs
- Tumeurs urologiques
- Tumeurs urogénitales
- Tumeurs par site
- Maladies rénales
- Maladies urologiques
- Adénocarcinome
- Tumeurs, glandulaires et épithéliales
- Tumeurs rénales
- Carcinome à cellules rénales
- Carcinome
- Effets physiologiques des médicaments
- Agents anti-infectieux
- Agents antiviraux
- Agents antinéoplasiques
- Agents immunosuppresseurs
- Facteurs immunologiques
- Inhibiteurs de l'angiogenèse
- Agents modulateurs de l'angiogenèse
- Substances de croissance
- Inhibiteurs de croissance
- Agents antibactériens
- Agents léprostatiques
- Interférons
- Thalidomide
Autres numéros d'identification d'étude
- 1500C
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur 5-Flourouracil, Interferon-a, IL-2 and Thalidomide
-
Temple UniversityComplétéLacérations | BlessuresÉtats-Unis
-
Coopervision, Inc.Complété
-
Kronoberg County CouncilMalmö UniversityComplétéComplication de l'appareil orthodontique
-
PfizerRésilié
-
AstraZenecaQuotient SciencesComplétéVolontaires en bonne santéRoyaume-Uni
-
ThinkWellUniversity of Oxford; Queen's University, Belfast; The BMJComplété
-
Universidade Federal de Santa MariaFranciscan University CenterComplétéSensibilité de la dentineBrésil
-
Thomas Jefferson UniversityAbbVieRecrutementSyndrome myélodysplasique | Syndrome myélodysplasique récurrent | Syndrome myélodysplasique réfractaireÉtats-Unis
-
National University Hospital, SingaporeComplétéHernie inguinale unilatérale primaireSingapour
-
Digna Biotech S.L.ComplétéInfection chronique par le virus de l'hépatite C | Génotype 1 | Patients déjà traités | RechutesEspagne